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Recent advances in molecular biology have led to the identifica-
tion of new molecular targets, such as epidermal growth factor
receptor (EGFR) mutations and echinoderm microtubule-associ-
ated protein-like 4 (EML4) – anaplastic lymphoma kinase (ALK)
fusion gene, in lung cancer. Dramatic response has been achieved
with EGFR inhibitors (gefitinib and erlotinib) and an ALK inhibitor
(crizotinib) in lung cancer expressing corresponding targets. How-
ever, cancer cells acquire resistance to these drugs and cause
recurrence. Known major mechanisms for resistance to molecular
targeted drugs include gatekeeper mutations in the target gene
and activation of bypass survival signal via receptors other than
the target receptors. The latter mechanism can involve receptor
gene amplification and ligand-triggered receptor activation as
well. For example, hepatocyte growth factor (HGF), the ligand of
a tyrosine kinase receptor Met, activates Met and the down-
stream PI3K/Akt pathway and triggers resistance to EGFR inhibi-
tors in EGFR mutant lung cancer cells. Moreover, EGFR ligands
activate EGFR and downstream pathways and trigger resistance
to crizotinib in EML4-ALK lung cancer cells. These observations
indicate that signals from oncogenic drivers (EGFR signaling in
EGFR-mutant lung cancer and ALK signaling in EML4-ALK lung
cancer) and ligand-triggered bypass signals (HGF-Met and EGFR
ligands-EGFR, respectively) must be simultaneously blocked to
avoid the resistance. This review focuses specifically on receptor
activation by ligand stimulation and discusses novel therapeutic
strategies that are under development for overcoming resistance
to molecular targeted drugs in lung cancer. (Cancer Sci 2012; 103:
1189–1194)
L ung cancer is the leading cause of cancer death worldwide.Several oncogenic drivers, including epidermal growth fac-
tor receptor (EGFR) mutations(1,2) and echinoderm microtu-
bule-associated protein-like 4 (EML4) – anaplastic lymphoma
kinase (ALK) fusion gene,(3) have been recently discovered in
lung cancer. Dramatic results have been achieved with EGFR
inhibitors(4,5) and an ALK inhibitor(6) in lung cancer express-
ing corresponding targets, and a paradigm shift in treatment is
occurring. However, some patients who have responded to
those inhibitors acquire resistance to them within a few years
and experience the recurrence of cancer.(7,8) This clinical issue
now needs to be resolved.
A gatekeeper mutation occurring at the binding site of a
molecular targeted drug is a typical mechanism for develop-
ment of acquired resistance.(9) Another crucial mechanism is
bypass signals to prevent apoptosis.(10) In addition to receptor
gene alterations (e.g. gene mutations and gene amplification)
besides target genes, activation of receptors by ligands plays
an important role in bypass signaling.(11) In recent years, vig-
orous attempts have been made to overcome resistance
through therapies combining drugs that alleviate resistance due
to gatekeeper mutations and drugs that block bypass signals.
This paper reviews resistance to molecular targeted drugs
caused by receptor activation as a result of ligand stimulation.
Using lung cancer as an example, this paper describes the
molecular mechanisms for that resistance and therapies to
overcome it.
Oncogenic Drivers of Lung Cancer
Alteration in genes such as KRAS,(12) EGFR,(1,2) EML4-ALK,(3)
DDR2,(13) and ROS(14) are known to be oncogenic drivers for
lung cancer. Selective inhibitors of EGFR gene mutations and
the EML4-ALK fusion gene have been developed and the clini-
cal efficacy of these drugs has been demonstrated,(4–6,15) result-
ing in their routine clinical use. EGFR gene mutations such as
exon 19 deletion and a point mutation in L858R in exon 21
cause activation of EGFR; the two account for 90% or more of
the EGFR gene mutations overall.(16) Lung cancers with such
EGFR-activating mutations respond to a reversible EGFR-tyro-
sine kinase inhibitors (TKIs) such as gefitinib or erlotinib at a
rate of 70–80%.(7) Recent phase III clinical trials revealed that
EGFR-TKI therapy to treat lung cancer with EGFR-activating
mutations resulted in a median survival time (MST) of about
30 months.(4,5) This is clearly a breakthrough in treatment,
given that the usual MST for non-small cell lung cancer is 10
–14 months.(17,18) EML4-ALK is a fusion gene that was first dis-
covered as a factor for the development of lung cancer, which
are considered typical solid tumors.(3) EML4-ALK is found in
about 5% of cases of pulmonary adenocarcinoma. EML4-ALK
lung cancer is highly prevalent in patients with pulmonary ade-
nocarcinoma who are never or light smokers and aged 50 and
under and rarely found in patients with EGFR-activating muta-
tions or KRAS mutations.(3,19) Histologically, the cancer often
produces an acinar pattern.(19) The cancer responds well (60%
and more) to crizotinib,(6,8) which has ALK-inhibiting activity,
and has a prognosis on par with EGFR-mutant lung cancer trea-
ted with EGFR-TKI therapy.
Nevertheless, most patients who have lung cancer with
EGFR-activating mutations and who have undergone EGFR-
TKI therapy or who have EML4-ALK lung cancer and who
have undergone ALK inhibitor therapy acquire resistance
after several years and experience recurrence of the cancer. In
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addition, 20–30% of patients fail to respond to the EGFR-TKI
or ALK inhibitor despite having EGFR mutations or the
EML4-ALK fusion gene. In other words, patients with initial
resistance pose a clinical problem.
Major Mechanisms for Resistance to Molecular Targeted
Drugs in Lung Cancer
Known mechanisms for resistance to targeted drugs include
gene mutations produced at the drug’s binding site (gatekeeper
mutations, such as EGFR-T790M and ALK-L1196M),(20–22)
activation of bypass signals via receptors other than the target
receptors (Met activation in EGFR-TKI resistance),(11,23) target
gene amplification (ALK amplification in ALK-TKI resis-
tance),(24) and activation downstream of the target.(25–27) The
activation of receptors other than the target receptors can
involve amplification of receptor genes or ligand stimulation.
This paper focuses specifically on receptor activation by ligand
stimulation and reviews recent findings.
Mechanisms of Resistance to EGFR-TKIs
Epidermal growth factor receptor-mutant lung cancer is extre-
mely sensitive to gefitinib and erlotinib. Table 1 shows the
major resistance mechanisms to EGFR-TKIs. Hepatocyte
growth factor (HGF),(28,29) a ligand of the tyrosine kinase
receptor Met, has been found to bind to Met and activate the
phosphatidylinositol 3-kinase (PI3K)/Akt pathway, thereby
inducing EGFR-TKI resistance(11) (Fig. 1). Hepatocyte growth
factor is a factor produced by lung cancer cells(30,31) as well as
by stromal cells (microenvironments) such as fibroblasts.(32)
Hepatocyte growth factor is involved in the carcinogenesis,(33)
invasion/motility,(34) epithelial-to-mesenchymal transition
(EMT),(35) angiogenesis,(36) and metastasis(37) in lung cancer,
and therefore associates with poor prognosis of the
patients(38,39) (Fig. 2). Moreover, regardless of whether it is
produced by cancer cells or fibroblasts, HGF induces EGFR-
TKI resistance.(40) None of the other receptor ligands, includ-
ing EGF, transforming growth factor (TGF)-a, and insulin-like
growth factor (IGF)-1, could induce EGFR-TKI-resistance in
EGFR mutant lung cancer cells,(11,41) indicating that EGFR-
TKI resistance is induced selectively by HGF.
To determine the clinical significance of resistance triggered
by HGF, a joint study of Japanese patients with EGFR-mutant
lung cancer was conducted at 12 facilities.(42) The study ana-
lyzed the prevalence of HGF, T790M, and Met amplification
in tissues from patients with EGFR-TKI resistance (Fig. 3). Of
23 tumors with acquired resistance, 14 had high levels of HGF
expression (61%), 12 had T790M (52%), and two had Met
amplification (9%). High levels of HGF expression were
detected most often. Of 45 tumors that did not respond to
EGFR-TKI despite having EGFR mutations, 13 had high levels
of HGF expression (29%), 0 had T790M (0%), and two had
Met amplification (4%). High levels of HGF expression were
again detected most often. Results thus suggested that HGF
induces acquired and intrinsic resistance to EGFR-TKI and is
the most prevalent factor for resistance, at least in Japanese
patients with EGFR-mutant lung cancer. Therefore, HGF is an
important therapeutic target for overcoming EGFR-TKI resis-
tance in EGFR mutant lung cancer.
In all of the patients with acquired resistance, HGF origi-
nated from cancer cells. Interestingly, two of 13 patients with
intrinsic resistance had high levels of HGF (15%) expressed
by stromal cells rather than cancer cells. Expression of HGF is
Fig. 1. Resistance signals to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) in EGFR mutant lung cancer cells. (a)
Mutant EGFR associates with ErbB3 and transduces survival signal through PI3K/Akt pathway. (b) EGFR-TKIs, such as gefitinib and erlotinib, bind
to tyrosine kinase domain of mutant EGFR and shut off the signal and induce apoptosis. (c) EGFR-T790M gatekeeper mutation results in prevent-
ing EGFR-TKIs to bind EGFR, and thereby induces resistance. (d) Amplified Met associates with ErbB3, transactivates the downstream signaling
pathway, PI3K-Akt, and thereby induces resistance. (e) Hepatocyte growth factor (HGF) phosphorylates Met and activates PI3K-Akt pathway,
independent of EGFR or ErbB3, and thereby induces resistance. “P” indicates phosphorylation.
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enhanced by inflammatory cytokines (IL-1, TNF, and IFN) and
suppressed by TGF-b.(29) However, mechanisms for the
enhanced expression of HGF by cancer-associated fibroblasts
(CAF) or lung cancer cells as leads to EGFR-TKI resistance
have yet to be clarified.
Relationships between resistance factors themselves. The
aforementioned analysis found that no tumors expressed both
T790M and Met amplification at the same time. This corrobo-
rates previous results indicating that T790M and Met amplifi-
cation are almost mutually exclusive.(26,41,43) An interesting
finding is that six of 12 tumors expressing T790M were found
to also have high levels of HGF expression while one of two
tumors with Met amplification also had high levels of HGF
expression.(42) Thus, HGF is often joined by other factors for
resistance, such as T790M and Met amplification. The biologi-
cal significance of this coexistence is described below.
HGF and Met amplification. Although Turke et al.(41) only
noted the phenomenon in the HCC827 cell line, they reported
that small numbers of cancer cells with Met amplification
(0.14%) may already be present. In the presence of EGFR-
TKI, HGF promotes the selection of cells with Met amplifica-
tion and encourages the emergence of resistance through Met
amplification. Similarly, examination of clinical specimens
from specific patients yielded results indicating the phenome-
non whereby HGF accelerated Met amplification by expanding
pre-existing Met-amplified clones.
Hepatocyte growth factor and T790M. Onizuka et al.(44) ana-
lyzed tissues from 10 patients with EGFR-mutant lung cancer
who developed acquired resistance to gefitinib. They detected
T790M in seven patients, and they reported that HGF was
overly expressed in five of six patients that were available for
analysis. In 27 patients who developed acquired resistance to
gefitinib or erlotinib, Turke et al.(41) detected T790M in 15. Of
the 15, 11 (73%) had increased levels of expression, compared
with levels before treatment, or high levels of HGF expression.
Thus, HGF often co-exists with T790M.
Irreversible EGFR-TKIs that form a covalent bond with
EGFR were expected to alleviate resistance due to a secondary
EGFR mutation, the T790M mutation, and its clinical develop-
ment is underway. However, irreversible EGFR-TKIs have not
performed as well as expected in numerous clinical trials con-
ducted here in Japan and abroad.(45) The current authors found
Fig. 2. Role of hepatocyte growth factor (HGF)-Met in lung cancer.
Hepatocyte growth factor is involved in the carcinogenesis, invasion/
motility, epithelial-to-mesenchymal transition (EMT), angiogenesis, and
metastasis, and therefore associates with poor prognosis of lung cancer.
Moreover, HGF triggers resistance of EGFR mutant lung cancer cells to
reversible epidermal growth factor receptor-tyrosine kinase inhibitors
(EGFR-TKIs), irreversible EGFR-TKIs, and mutant EGFR selective TKIs.
Table 1. Major mechanisms of epidermal growth factor receptor-
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Fig. 3. Incidence of resistance factors in EGFR mutant lung cancer
resistant to epidermal growth factor receptor-tyrosine kinase inhibi-
tors (EGFR-TKIs). Results of a joint study of Japanese patients with
EGFR-mutant lung cancer conducted at 12 facilities to determine the
clinical significance of resistance triggered by hepatocyte growth fac-
tor (HGF). (a) Of 23 tumors with acquired resistance, 14 had high lev-
els of HGF expression (61%), 12 had T790M (52%), and two had Met
amplification (9%). High levels of HGF expression were detected most
often. T790M and HGF are often both present in tumors that have
developed acquired resistance to gefitinib and erlotinib. (b) Of 45
tumors that did not respond to EGFR-TKI despite having EGFR muta-
tions, 13 had high levels of HGF expression (29%), 0 had T790M (0%),
and two had Met amplification (4%). High levels of HGF expression
were again detected most often. These results suggest that HGF
induces acquired and intrinsic resistance to EGFR-TKI and is the most
prevalent factor for resistance.
Yano et al. Cancer Sci | July 2012 | vol. 103 | no. 7 | 1191
© 2012 Japanese Cancer Association
that HGF induced resistance to reversible EGFR-TKIs as well
as to irreversible EGFR-TKIs.(46,47) T790M and HGF are often
both present in tumors that have developed acquired resistance
to gefitinib and erlotinib, suggesting that high levels of HGF
expression in a tumor may be a reason why irreversible
EGFR-TKIs have not been effective in clinical trials. Presum-
ably, a combination of an HGF inhibitor and irreversible
EGFR-TKI would be of clinical benefit in treating tumors with
high levels of HGF expression.
Involvement of other receptor ligands. In squamous cell
carcinoma (carcinomas of the head and neck and cervical
carcinoma) models with cancer harboring wild-type EGFR,
EGFR-TKI resistance due to activation of IGF-1R have been
reported in preclinical models.(48) Acquired resistance due to
activation of IGF-1R has not yet been demonstrated in EGFR-
mutant lung cancer.
Some lung cancer patients who respond well to treatment with
EGFR-TKIs, and who later experience therapy failure, demon-
strate a second response to EGFR-TKI re-treatment after a “drug
holiday”.(49) Recent study showed that activation of IGF-1R
may be involved in a reversible “drug-tolerant” state,(50) though
this has yet been proven in studies with clinical specimens.
Mechanisms of Resistance to Anti-EGFR Antibody
Cetuximab, a chimeric anti-EGFR antibody, had a statistically
significant survival benefit when used together with anticancer
agents to treat advanced non-small cell lung carcinoma (FLEX
trial).(51) Subsequent biomarker analysis revealed that cetux-
imab was more efficacious in patients with high levels of EGFR
expression than in those with low levels of EGFR expres-
sion.(52) Elucidation of the molecular mechanisms of cetuximab
resistance in patients with high levels of EGFR expression
should thus help to sustain the benefits of treatment.
Yamada et al.(53) examined mechanisms for cetuximab resis-
tance using lung cancer cell lines expressing high levels of
wild-type EGFR or mutant EGFR. Both H292 (wild-type
EGFR) and Ma-1 (EGFR-mutant; exon 19 deletion) cell lines
were sensitive to cetuximab, but HGF induced cetuximab resis-
tance by activating PI3K/Akt pathway (Fig. 4). In a xenograft
model in SCID mice, H292 tumors inoculated with fibroblasts
producing large amounts of HGF were resistant to cetuximab.
Cancer-associated fibroblasts may express high levels of HGF
depending on the patient.(40) These observations suggest that in
clinical settings there are some patients in whom CAFs express
high levels of HGF and induce cetuximab resistance. This find-
ing needs to be verified using clinical specimens.
Mechanisms of Resistance to ALK-TKIs
Crizotinib, an ALK-TKI, responds well to EML4-ALK lung can-
cer (60% or more) and has therapeutic efficacy comparable to
that of EGFR-TKI in treating EGFR-mutant lung cancer. How-
ever, almost every patient who responds well to crizotinib will,
without exception, experience recurrence due to acquired resis-
tance.(12) The mechanisms for acquired resistance include gate-
keeper L1196M mutations,(22) ALK gene amplification,(24) and
other ALK gene mutations (L1152R, C1156Y, F1174L).(54–57)
With regard to resistance due to ligands, EGFR ligands
(EGF, amphiregulin, HB-EGF, and TGF-a) are reported to
induce crizotinib resistance. Sasaki et al.(55) reported that cells
derived from pleural effusions of patients with EML4-ALK lung
cancer who developed acquired resistance to crizotinib dis-
played the gatekeeper L1196M mutation and high levels of
expression of EGFR ligands (EGF and amphiregulin). This sug-
gests the existence of a mechanism of resistance due to activa-
tion of an EGFR pathway in an autocrine manner. We reported
that exogenously added EGFR ligands activated EGFR pathway
and induced resistance to crizotinib in a paracrine manner
(Fig. 4).(58) Crizotinib has Met-inhibiting action, so HGF did
not induce crizotinib resistance. Other receptor ligands, such as
IGF-1 and platelet-derived growth factors (PDGFs), also failed
to induce resistance. These observations indicate that when the
signal of EML4-ALK, an oncogenic driver, is blocked in
EML4-ALK lung cancer cells, a bypass signal from another
receptor will be activated, leading to resistance.
Preclinical studies have indicated that selective ALK inhibi-
tors (TAE684 and CH5424802) are effective in alleviating
gatekeeper mutations and ALK gene amplification that induce
acquired resistance to crizotinib.(56,59) This should lead to
Fig. 4. Ligand-triggered resistance to epidermal growth factor receptor (EGFR) inhibitors and anaplastic lymphoma kinase (ALK) inhibitors. (a)
In EGFR mutant lung cancer cells, hepatocyte growth factor (HGF) activates Met and downstream PI3K/Akt pathway and triggers resistance to
EGFR-tyrosine kinase inhibitors (TKIs). (b) In EGFR wild type lung cancer cells, HGF activates Met and downstream PI3K/Akt pathway and triggers
resistance to anti-EGFR antibody, cetuximab. (c) In EML4-ALK lung cancer cells, EGFR ligands activate EGFR and downstream PI3K/Akt and ERK1/2
pathways and triggers resistance to crizotinib.
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better clinical performance by selective ALK inhibitors, and
clinical trials of selective ALK inhibitors are underway. How-
ever, resistance is anticipated to occur with selective ALK
inhibitors as well, and elucidation of the mechanisms by which
it occurs is crucial. Yamada et al. found that both HGF and
EGFR ligands induce resistance to the selective ALK inhibitor
TAE684.(58) This finding indicates that a selective ALK inhibi-
tor produces greater effect against resistance caused by gate-
keeper mutation and amplification in ALK than does crizotinib,
but it also suggests that resistance due to bypass signaling may
occur more readily than would occur with crizotinib. Results
of clinical trials should indicate whether a selective ALK
inhibitor or multikinase inhibitor like crizotinib is more effec-
tive at treating EML4-ALK lung cancer.
Treatments for Resistance Due to Ligand Stimulation
Signals from oncogenic drivers (EGFR signaling in EGFR-
mutant lung cancer and ALK signaling in EML4-ALK lung
cancer) and bypass signals that trigger resistance (HGF-Met
and EGFR ligands-EGFR) must be simultaneously blocked to
avoid resistance caused by bypass signaling as a result of
ligand stimulation.
Hepatocyte growth factor-Met can be inhibited by Met-TKI,
HGF-neutralizing antibody,(11,40,60) or inhibitors of HGF-Met
binding such as anti-Met monoclonal antibody MetMAb(61)
and natural antagonist NK4.(40) Inhibitors of downstream mole-
cules, such as PI3K and mammalian target of rapamycin
(mTOR), can be also used.(62) The current authors have indi-
cated in in vitro and in vivo models that resistance due to
HGF can be alleviated by combined use of EGFR-TKI (gefiti-
nib or erlotinib) and such an inhibitor (Fig. 5).(40,41,46,47,59,61)
Epidermal growth factor receptor-TKIs and anti-EGFR anti-
body can be used to inhibit EGFR ligands and EGFR (both are
used clinically), and resistance to ALK inhibitors can be alle-
viated through combined use of those EGFR inhibitors.
Conclusion
Mechanisms for resistance to molecularly targeted drugs have
gradually been clarified, and strategies to treat that resistance
have been indicated. In lung cancer, Met and EGFR pathways
are important for transduction of a bypassing signal to survive,
but their receptors also play an important role in hemostasis
in vivo.(29) Thus, the efficacy and safety of therapy by blocking
these pathways for long periods must be carefully verified. In
many instances, an individual may have several resistant
tumors and multiple mechanisms of resistance may be at work.
Thus, optimal treatment for each patient requires accurate
diagnosis of the mechanism by which the individual patient
developed resistance. In such instances, a second biopsy is rec-
ommended,(26) but in the event of multiple lesions all of their
origins would have to be biopsied, a feat that would be rather
difficult. A highly reliable, minimally invasive diagnostic tech-
nique needs to be developed to achieve that goal.
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